Integra Lifesciences vs Penumbra
Integra Lifesciences reported revenue of $1.6 billion in fiscal 2025, 1.2 times Penumbra's $1.4 billion in fiscal 2025. Integra Lifesciences' revenue grew 1.5% in its latest year, and Penumbra's grew 17.5%. Integra Lifesciences had an operating margin of -30.2%, against 13.5% at Penumbra. Free cash flow was −$31 million at Integra Lifesciences and $175 million at Penumbra.
Side by side
| Integra Lifesciences | Penumbra | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.6B | $1.4B |
| Revenue growth | 1.5% | 17.5% |
| Revenue growth a year, last 5 years | 3.6% | 20.2% |
| Gross margin | 50.9% | 67.1% |
| Operating margin | −30.2% | 13.5% |
| Net margin | −31.6% | 12.7% |
| Free cash flow | −$31M | $175M |
| Free cash flow margin | −1.9% | 12.5% |
| Return on capital | −22.0% | 18.8% |
| Net debt to EBITDA | — | −2.5x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −0.4% | 0.1% |
| Last close | $12.10 | $325.22 |
| P/E at the last close | 71.2× | 79.9× |
| Insider trades, last 12 months | bought $102,150, sold $0 | sold $11.1 million |
| Piotroski F-score | 5 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Integra LifesciencesPenumbra
Operating margin
Percent of revenue
Integra LifesciencesPenumbra
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Integra LifesciencesPenumbra
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Integra Lifesciences and Penumbra pages.